## Prognostic value of Bone Scan Index for survival in patients with prostate cancer

**Mariana Reza¹, Anders Bjartell², Lars Edenbrandt¹, Mattias Ohlsson², Per Wollmer¹, Elin Trägårdh¹**  
Depts of ¹Clinical Sciences Malmö and ²Theoretical physics, Lund University, Sweden

**Disclosure:** Edenbrandt and Ohlsson are stockholders in EXINI Diagnostics AB (Lund, Sweden)

### Background and Aim

- **Bone Scan Index (BSI)** is a measurement that reflects the extension of tumor in bone as a percent of the total skeletal mass calculated from Bone Scans.
- What do we know about it? BSI has been proposed both as a prognostic biomarker and as a response biomarker in prostate cancer (PCa) patients.
- Why is it now more interesting? Recently, an automated method to calculate BSI was developed, which makes it feasible to use in clinical routine.

**Aim** To evaluate the prognostic value of BSI as a response biomarker in prostate cancer patients after hormonal therapy.

### Results

**Kaplan Meier curves** showing patient-survival probability stratified by Bone Scan Index (BSI) groups.

Both BSI at follow-up and changes in BSI compared to BSI before treatment are significantly associated with survival.

**Cox proportional hazards regression analysis**  
In a multivariate analysis, BSI at follow-up (p<0.001) was associated with survival, but PSA (p=0.13) was not prognostic.

### Bone Scan Index - BSI

BSI is an Imaging biomarker that reflects the tumor burden in bone as a percent of the total skeletal mass.

- **At diagnosis**  
  BSI= 1.1

- **After hormonal therapy**  
  BSI= 1.4

### Patients and Methods

- **101 Prostate Cancer Patients**  
  - Consecutive group  
  - Retrospective analysis  
  - High risk at the time of diagnosis: Clinical stage T2c/T3/T4, Gleason score 8-10 or PSA level >20 ng/mL.

- **Whole-body bone scans**  
  - At the time of diagnosis – Before treatment  
  - After hormonal therapy  
  - BSI calculated using the automated software EXINI Bone™

- **Clinical and Survival Data**  
  - T stage, Gleason score, prostate-specific antigen (PSA), treatment and survival data were collected from computerized medical records.

### Conclusions

**Advances in Knowledge**

- BSI is highly associated with 5-year survival in prostate cancer.
- Treatment response after hormonal therapy can be evaluated with BSI.
- Increase in BSI can be used as an indicator for progress.

**Implications for patient care**

- BSI can be used to risk-stratify prostate cancer patients.
- BSI can be a complement to PSA in patient management.
- Automated BSI method available for clinical routine use.

**Clinical relevance**

Life expectancy is a major factor to be considered in the management of prostate cancer patients. Risk-stratification schemes based on clinical T stage, Gleason score and PSA are widely used to estimate risk in individual patients. The extent of bone metastases is also associated with survival, but there has not been any clinically useful technique of quantifying the skeletal tumour burden and including this information in the risk assessment.